Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces Rasilez provides greater reduction in high blood pressure

Novartis announces Rasilez provides greater reduction in high blood pressure

12th November 2008

Novartis has announced that its Rasilez provides greater reduction in high blood pressure by an additional 2.3 mmHg in patients aged 65 and over.

The comments follow an Ageless study – presented to the American Heart Association – which showed that the product provides an additional reduction in systolic blood pressure, compared to the ACE inhibitor ramipril.

The research saw 900 patients aged 65 and over with systolic hypertension undergo the treatment over 12 weeks, with a greater reduction of diastolic blood pressure achieved.

Lead author of the Ageless study and director of research at the Rasmussen Centre for Cardiovascular Disease Prevention at the University of Minnesota, US, Daniel Duprez, said: “The elderly population is expected to more than double over the next thirty years. Therefore, it is important to have effective therapies such as aliskiren to treat a range of patients, including the elderly.”

Recent Epidemiology of Hypertension in the Elderly figures found that 70 per cent of people aged over 60 have high blood pressure, with increased systolic blood pressure – the pressure of blood flow when the heart beats – being the most frequent type of uncontrolled high blood pressure.

The condition is associated with an increased risk of cardiovascular events including stroke, myocardial infarction and heart failure.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.